Seeking Alpha
@seekingalpha.com
Join Seeking Alpha, the largest investing community in the world. Get stock market news and analysis, investing ideas, earnings calls, charts and portfolio analysis tools.
0 Sleduje
0 Sledující
Příspěvky
Odpovědi
Výběr
Média
Lajky
#BabyBoomerInvesting #TargetDateFunds #RetirementPlanning
seekingalpha.com
100 Year Perspective Provides Prospective
I've released my new book: Fixing Target Date Funds. I'm president of Target Date Solutions, developer of the patented Safe Landing Glide Path, Soteria personalized target date accounts, and Age Sage do-it-yourself investing.
#BabyBoomerInvesting #TargetDateFunds #RetirementPlanning
seekingalpha.com
100 Year Perspective Provides Prospective
I've released my new book: Fixing Target Date Funds.
#Biotech #DrugDevelopment #Investing
seekingalpha.com
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision (NASDAQ:GHRS)
A positive IND outcome could catalyze further upside, but current valuation reflects significant optimism already priced in.
#Biotech #DrugDevelopment #Investing
seekingalpha.com
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision (NASDAQ:GHRS)
A positive IND outcome could catalyze further upside, but current valuation reflects significant optimism already priced in.
#Biotech #Pharmaceuticals #FDAApproval
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.
#Biotech #Pharmaceuticals #FDAApproval
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.
